1	Integration of Machine Learning to Identify Diagnostic Genes in Leukocytes
2	for Acute Myocardial Infarction Patients
3	Lin Zhang ^{1*} , Yue Liu ^{2*} , Kaiyue Wang ¹ , Xiangqin Ou ³ , Jiashun Zhou ⁴ , Houliang Zhang ⁴ ,
4	Min Huang ² , Zhenfang Du ^{2#} , Sheng Qiang ^{2#}
5	¹ State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional
6	Chinese Medicine, 10 Poyanghu Road, Jinghai, Tianjin 301617, P. R. China.
7	² Department of Nephropathy, Zhangjiagang TCM Hospital Affiliated to Nanjing University of
8	Chinese Medicine, Zhangjiagang, Jiangsu 215600, P. R. China.
9	³ The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang,
10	Guizhou 550025, P. R. China.
11	⁴ Tianjin Jinghai District Hospital, 14 Shengli Road, Jinghai, Tianjin 301699, P. R. China.
12	
13	* Lin Zhang and Yue Liu contributed equally.
14	# Corresponding author
15	Sheng Qiang, Department of Nephropathy, Zhangjiagang TCM Hospital Affiliated to Nanjing
16	University of Chinese Medicine, Zhangjiagang, Jiangsu 215600, P. R. China.
17	Email address: <u>giangsheng660@163.com.</u>
18	Zhenfang Du, Department of Nephropathy, Zhangjiagang TCM Hospital Affiliated to Nanjing
19	University of Chinese Medicine, Zhangjiagang, Jiangsu 215600, P. R. China.
20	Email address: <u>zyydzf@163.com.</u>
21	

22 Abstract:

23	Background: Acute myocardial infarction (AMI) has two clinical characteristics: high missed
24	diagnosis and dysfunction of leukocytes. Transcriptional RNA on leukocytes is closely related to
25	the course evolution of AMI patients. We hypothesized that transcriptional RNA in leukocytes
26	might provide potential diagnostic value for AMI. Integration machine learning (IML) was first
27	used to explore AMI discrimination genes. The following clinical study was performed to validate
28	the results.
29	Methods: A total of four AMI microarrays (derived from the Gene Expression Omnibus) were
30	included in this study (220 sample size), and the controls were identified as patients with stable
31	coronary artery disease (SCAD). At a ratio of 5:2, GSE59867 was included in the training set,
32	while GSE60993, GSE62646, and GSE48060 were included in the testing set. IML was explicitly
33	proposed in this research, which is composed of six machine learning algorithms, including
34	support vector machine (SVM), neural network (NN), random forest (RF), gradient boosting
35	machine (GBM), decision trees (DT), and least absolute shrinkage and selection operator
36	(LASSO). IML had two functions in this research: filtered optimized variables and predicted the
37	categorized value. Furthermore, 40 individuals were recruited, and the results were verified.
38	Results: Thirty-nine differentially expressed genes (DEGs) were identified between controls and
39	AMI individuals from the training sets. Among the thirty-nine DEGs, IML was used to process
40	the predicted classification model and identify potential candidate genes with overall normalized
41	weights >1. Finally, Two genes (AQP9 and SOCS3) show their diagnosis value with the area
42	under the curve $(AUC) > 0.9$ in both the training and testing sets. The clinical study verified the

43	significance of AQP9 and SOCS3. Notably, more stenotic coronary arteries or severe Killip
44	classification indicated higher levels of these two genes, especially SOCS3. These two genes
45	correlated with two immune cell types, monocytes and neutrophils.
46	Conclusion: AQP9 and SOCS3 in leukocytes may be conducive to identifying AMI patients with
47	SCAD patients. AQP9 and SOCS3 are closely associated with monocytes and neutrophils, which
48	might contribute to advancing AMI diagnosis and shed light on novel genetic markers. Multiple
49	clinical characteristics, multicenter, and large-sample relevant trials are still needed to confirm its
50	clinical value.
51	Keywords: Acute Myocardial Infarction, Diagnostic Gene Identification, Machine Learning,
52	AQP9, SOCS3, Immune Cell Correlation
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	

64 1 Introduction

65	Acute myocardial infarction (AMI), the most severe form of cardiovascular disease, is associated
66	with [1, 2] millions of deaths annually around the world [3, 4]. Generally, the diagnosis of AMI
67	includes clinical syndrome, electrocardiogram, and serum changes in enzyme levels [5]. However,
68	AMI is easily misdiagnosed because of the following three aspects: nonclassic clinical symptoms
69	[6, 7], atypical underappreciation [8], and an untimely serum peak. Because of the above three
70	problems, a previous study [9] reported that the missed diagnosis rate of AMI is higher than 0.9%.
71	The diagnosis and treatment of AMI must be prompt; otherwise, it may trigger irreversible results.
72	Therefore, exploring new markers of AMI to decrease missed diagnoses is essential and urgent.
73	
74	Leukocytes play an important and varied role in the entire evolution of AMI. During the acute
75	injury phase of AMI, leukocytes promote a severe inflammatory cascade response through the
76	polarization of M1 macrophages [10]. During the repair phase of AMI, M2 macrophages in
77	leukocytes suppress inflammation and mediate the repair of injured myocardium [11].
78	Furthermore, leukocyte alteration positively correlates with AMI severity and, inversely, with
79	patient survival [12, 13].
80	

RNAs are involved in the evolution of AMI. For example, miR-155 correlated positively with the
concentration of inflammatory cytokines - IL-6 and TNF-α [14] in AMI. Neutrophil-derived
S100A8/A9 amplify granulopoiesis and cardiac injury in AMI mice [15]. Conversely, M2
macrophage-derived exosomes carry miR-1271-5p [16] to alleviate AMI-related cardiac injury. In

85	conclusion, RNA on leukocytes plays a different role in the evolution of AMI, possibly related to
86	different leukocyte subtypes. However, numerous studies have focused on integrating target
87	interventions [12, 17] and leukocyte complications [17, 18]. Few studies have focused on the
88	diagnostic value of leukocytes' RNA. Because the leukocytes' RNA is involved in the evolution of
89	AMI, these RNA might have diagnosing value for AMI patients. The diagnosis value might be
90	related to various leukocyte subtypes.

91

92 Machine learning (ML) helps humans learn patterns from complex data to predict future 93 behavioural outcomes and trends. ML was widely utilized in variable filtering. A previous study 94 used a single ML algorithm or two integrated ML algorithms (e.g., support vector machine [18] or 95 least absolute shrinkage and selection operator [19]) to optimize variables. Still, these approaches 96 may have missed potential genes [20]. Compared with a single ML algorithm, the integrated ML 97 (IML) approach [21-23] we developed is more advantageous in variable screening and model 98 building. IML helps identify potential genes mistakenly deleted by a single ML and find more 99 meaningful variables [21]. IML integrates the advantages of a single ML, and its predictive 100 classification value is better [23]. Based on a favourable filtration value in transcriptomics of IML, 101 IML might be used to comprehensively explore the diagnostic value in AMI patients.

102

In summary, we aim to explore the potential diagnostic value of transcriptome within leukocytes
for identifying AMI patients. Because of IML's good variable screening and excellent predictive
value, IML was first used to mine diagnostic genes in AMI leukocytes with multiple microarrays.

106	Single microarray data might have inherent biases in capturing the entire transcriptomic landscape,
107	so multiple microarrays are integrated after resolving batch effects to reduce bias and validate
108	each other. And clinical validation was added to confirm the result. The relationship between
109	transcriptome and leukocyte subtypes was unclear, so the correlation between immune cells and
110	target transcriptome was subsequently accomplished. We expect to explore the functional roles of
111	the identified genes in AMI pathophysiology, investigating their potential as therapeutic targets.
112	

114 **2.1 Data acquisition**

2 Methods

113

115	The raw data were obtained from the Gene Expression Omnibus (GEO, March 27, 2022). AMI
116	patients have similar symptoms to SCAD patients, which were set as the controls. An increasing
117	leukocyte may influence the result of other cardiovascular diseases (e.g., stroke [24, 25] and
118	heart failure [26]), to be excluded. AMI is easily misdiagnosed as SCAD. Leukocytes are also
119	altered in other cardiovascular diseases. Based on the above, the following inclusion and
120	exclusion criteria were set: I) inclusion criteria-(i) diagnosed as AMI patients on admission; (ii)
121	transcriptome was obtained from leukocytes in blood; (iii) initial data were free and accessible;
122	and (iv) the control individuals were diagnosed with stable coronary artery disease (SCAD); and
123	II) exclusion criteria—(i) other cardiovascular diseases suspected and (ii) blood were taken more
124	than one day after hospitalization.

125

126 2.2 Data processing

127	To ensure the reliability of the data, the R package sva (version 3.46.0) was applied to data
128	integration to minimize the branch effects with the ComBat function and parametric adjustments.
129	Regarding the distribution ratio of previous literature (1.64:1 [27] to 5:1 [28]) and to minimize the
130	branching effect, this research was distributed in the training or testing sets at a ratio of 5:2.
131	GSE59867 was included in the training set. In contrast, GSE60993, GSE62646, and GSE48060
132	were included in the testing set. In brief, the training set was applied to explore candidate
133	diagnostic genes, and the testing set was used for validation. Based on the differential DEGs,
134	three functional enrichment analyses were developed via the Kyoto Encyclopedia of Genes and
135	Genomes Gene Set Enrichment Analysis (KEGG-GSEA), Gene Ontology (GO), and Disease
136	Ontology (DO). In addition, the GO terms included three branches: molecular function (MF),
137	biological process (BP), and cellular components (CC). Notably, the novel IML served two
138	functions: developing classification ML and exploring the candidate variable. Finally, the above
139	candidate genes were verified in the testing group and clinical study, and an immune analysis
140	among the candidate genes was performed. CIBERSORT was processed for immune correlation
141	analysis in the corrplot R package (version 0.92). And the primary code was link with
142	https://github.com/Linzhang-BiuBiuBiu/ML-for-diagnosis-genesgit.

143

144 **2.3 Searching for DEGs**

Because the same gene may have multiple sequences, the transcriptome will appear to have several expression data for the same genes. For the same genes, *limma* (version 3.54.0) was employed to identify the DEGs with the average gene expression. According to the Benjamini and

148	Hochberg	method,	two	thresholds	were	established:	an	absolute	value	of	fold	change

- (|logFC|) > 0.7 (previous studies were 0.5 [29]-1 [23]) and a false discovery rate [30] < 0.05.
- 150

151 2.4 IML of six ML algorithms

152	Classification models of IML, composed of six ML algorithms, were processed, covering support
153	vector machine (SVM), neural network (NN), random forest (RF), gradient boosting machine
154	(GBM), decision trees (DT), and least absolute shrinkage and selection operator (LASSO). In
155	brief, IML was used to identify candidate genes with the overall normalized weights. The six ML
156	algorithms were developed to optimize parameter settings, model development in the training sets,
157	and validation in the testing sets. For stability, all ML algorithms were tenfold cross-validated.
158	Notably, an accuracy value was applied to evaluate the predictive classification value, and a
159	higher accuracy value showed a better classification value of the six ML algorithms.
160	
161	LASSO [31] minimizes the sum of squares of the residuals when the sum of the absolute values

162 of the regression coefficients is less than a constant, producing specific regression coefficients

163 equal to 0 and filtering variables. LASSO was processed with the glmnet (version 4.1-6) R

- 164 package. *cv.glmnet* was utilized to majorize lambda. For the parameters, the scale of "lambda"
- 165 was set between 0 and 100 with "binomial" and "class".Based on the minimum lambda, *glmnet*
- 166 was processed to the LASSO with alpha and a "binomial" method in training sets.

167

168 SVM aim to find the separating hyperplane [32] that divides the dataset correctly with the largest

169	geometric interval	. SVM wa	is developed	with the	e1071	R package	(version	1.7–12).	tune.svn
-----	--------------------	----------	--------------	----------	-------	-----------	----------	----------	----------

170 was adopted to optimize the settings parameter with the kernel of "linear", and the cost between 1

171 and 20.

- 172
- 173 DT [33] is based on a tree structure that judges (one or more) sample attributes sequentially, from
- top to bottom, up to the leaf nodes of the decision tree and derives the final result. DT was
- processed with *rpart* (version 4.1.19) and *rpart.plot* (version 3.1.1). Based on the "class" method
- and a cp value of 0.001, the *rpart* function was adopted for the DT model.
- 177

RF use a " bagging " technique [34] to construct complete decision trees in parallel by randomly
self-sampling dataset samples and features. RF was completed with the R package *randomForest*(version 4.7-1.1). First, the *tuneRF* function was adopted to optimize 0-700 trees with one step
size. RF was developed based on the minimum error rate to optimize the number of trees.
NN outputs model [35] by inputting multiple nonlinear models and weighted interconnections
between various models. NN was processed with *neuralnet* (version 1.44.2) with *neuralnet*function, five layers (an input, an output, and three hidden layers), err.fct of "sse", and the linear.

186

GBM serially generates a series of weak learners [36], which are directly used to form the final model by combining them. Compared with the other 5 ML algorithms, GBM processed more steps and was prone to making mistakes. The GMB was developed with *h2o* (version 3.38.0.1).

190	First, the Java operating environment was installed, which is the virtual environment of GBM.
191	Essential for running the memory setting in h2o.init, the model memory of GBM was adjusted to
192	8G. The h2o data type in GBM was inevitable, and the <i>as.h2o</i> function was utilized to transform
193	the data format. Next, h2o.gbm tuned the parameters and developed the model with the
194	"Bernoulli" distribution, 200 trees, a learning rate of 0.001, and a sample rate of 90%.
195	
196	Furthermore, with the weights of the above six ML algorithms in DEGs, the normalized sum
197	weight of IML was calculated as follows: overall weights = $abs(RF)/abs(RFmax) + bbs(RFmax)$
198	abs(SVM)/abs(SVMmax) + abs(LASSO)/abs(LASSOmax) + abs(NN)/abs(NNmax) +
199	abs(GBM)/abs(GBMmax) + abs(DT)/abs(DTmax). For instance, if the weight of interleukin-6 in
200	six ML algorithms was 30, -22, 20, -2, 320, and -8, the maximum absolute value weights in the
201	six ML algorithms were 60, 88, 80, 8, 640, and 16. Therefore, the overall weight of interleukin-6
202	was $ 30 /60+ -22 /88+ 20 /80+ -2 /8+ 320 /640+ -8 /16=2.25$. With normalized overall weights >1,
203	the candidate genes were estimated by the area under the curve (AUC).
204	
205	2.5 Clinical validation
206	

The clinical trial was performed according to the Declaration of Helsinki guidelines. All AMI and SCAD patients provided individual written informed consent from October 10 2022, to December 31 2022, and the Ethics Review Committee of Jinghai District Hospital approved the study. There was no increase in the cost of treatment for the patients, no addition of other intervention in the

211	treatment, and the blood samples used were taken from the discarded blood of the patients after
212	their routine blood tests on the same day. If the patient did not have a routine blood test on that
213	day, then the patient was excluded. All AMI patients underwent coronary angiography, and blood
214	samples were collected in anticoagulant tubes on admission. Density gradient centrifugation [37,
215	38] was performed for leukocyte isolation. In brief, 8 mL of Ficoll solution was added to 8 mL of
216	anticoagulated blood, and the upper plasma layer was discarded after centrifugation. The white
217	cell layer at the isolate's junction was aspirated, added to 10mL of saline, and centrifuged; the
218	bottom layer was the leukocytes. RNA, isolated from leukocytes, was synthesized with reverse
219	transcription kits (Takara, Shiga, Japan). Quantitative reverse transcription PCR was executed on
220	an ABI7900HI (Thermo Fisher Scientific). According to previous literature, the relative content of
221	the candidate genes was scaled to the reference gene (GAPDH [39]), and Table 1 lists the primer
222	sequences.

223 **Table 1** List of primers for real-time PCR analysis in GAPDH, AQP9, and SOCS3.

224 3 Results

225 3.1 Included datasets

A total of 4 datasets (Table 2) (220 sample sizes), namely, GSE59867, GSE60993, GSE62646,

and GSE48060, were integrated for this study. The training set was obtained from GSE59867 (46

- 228 controls and 111 AMI patients) based on a raw ratio of 5:2. Furthermore, the testing set was
- 229 integrated with the other three datasets (28 controls and 35 AMI patients), namely, GSE60993,
- 230 GSE62646, and GSE48060. The following analysis is presented in **Fig 1**.

231

232	Table 2 Fundamental information in the four datasets.
233	
234	Fig. 1 The workflow of this study contains four parts: GEO datasets for training and testing sets, machine
235	learnings for classification and variable filtration, diagnosis value verification, and immune correlation.
236	3.2 DEG identification
237	Thirty-nine DEGs were identified (Table S1) in a training set from 17,049 RNAs. Compared to
238	the control group (SCAD), 28 genes were upregulated (SOCS3, HP, ECRP, AQP9, FAM20A,
239	CES1, STAB1, NRG1.1, NRG1, DYSF, RNASE1, RNASE2, ASGR2, CYP1B1, MERTK,
240	FCGR1A.2, MIR21, FCGR1A.1, TCN2, VSIG4, PPARG, FCGR1A, SLED1, S100A9, FMN1.1,
241	CD163, TMEM176A, and SERPINB2) and 11 genes were downregulated (KLRC3, KLRD1,
242	KLRA1P, DTHD1, KLRC4, MYBL1, CLC, KLRC2, KLRC4-KLRK1, SNORD20, and
243	SNORD45B) in AMI individuals (Fig. 2).
244	
245	Fig. 2 Heatmap and volcano plot of 39 DEGs in the AMI and control groups. A Red in the heat map indicates high
246	expression, and a blue indicates low expression. B Green in the volcano map suggests lower expression, and red
247	indicates high expression.
248	3.3 Functional analysis

Based on the above DEGs, 45 GSEA terms (**Table S2**) were identified, and the top 5 are shown in **Fig. 3A-B**; 160 GO terms (**Table S3**) were identified, and the top 5 are shown in **Fig. 3C**; and the top 10 of 57 DO terms (**Table S4**) are shown in **Fig. 3D**. In GSEA-KEGG of AMI, the top 3 were Fc gamma R-mediated phagocytosis, Huntington disease, and Leishmania infection. In GO, the

253 top 3 in BP were the stimulatory C-type lectin receptor signalling pathway, response to lectin, and

254 cellular response to lectin. In DO terms, the top 3 were atherosclerosis, arteriosclerotic

- 255 cardiovascular disease, and arteriosclerosis.
- 256
- 257

Fig. 3 Functional analysis of GSEA, GO, and DO terms. A The top 5 GSEA-KEGG pathways in controls. B The
top 5 GSEA-KEGG pathways in AMI patients. C The top 5 GO terms in BP, CC, and MF. D The top 15 DO terms.

260

261 3.4 IML of six ML algorithms

262 Six ML algorithms (Fig. 4) and their accuracies (Table 3) were assessed. Eight genes were 263 identified in LASSO (Fig. 4A), and the training and testing sets' accuracy value was 70.70% 264 (Table 3). In SVM, 13 genes were filtered (Fig. 4B), and the accuracies were 88.46% and 91.84%, 265 respectively. The error rate of RF (Fig. 4C) decreased with an increasing number of trees. Until 266 161 trees, the error rate of RF was minimized, and the accuracy of the two sets was 98.09% and 267 100%. In DT (Fig. 4D), the gene expression of 9.8 in AQP9 could discriminate the control and 268 AMI groups, while the accuracies were unstable, 94.27%, and 75.52%. In GBM (Fig. 4E), 6-fold 269 methods were established to optimize the diagnosis genes, but unstable accuracies, such as the 270 above ML algorithms, were 93.30% and 85.71%. In the NN (Fig. 4F), although sufficient for 271 discriminating the controls and AMI patients with three hidden layers, the accuracy was either 272 83.74% or 71.43%. Among the above ML algorithms, the raw weights of 39 DEGs were 273 identified (Table S5). Interestingly, RF had the highest and most stable accuracy value among all

274	ML algorithms. The normalized overall weights (Table 4) were calculated to filter the candidate
275	variables. Twenty-six genes (ASGR2, SOCS3, AQP9, PPARG, RNASE1, DYSF, S100A9,
276	FCGR1A, VSIG4, STAB1, MYBL1, KLRD1, ECRP, TCN2, FAM20A, MERTK, HP, RNASE2,
277	DTHD1, CLC, SNORD20, CD163, NRG1, SNORD45B, CYP1B1, and KLRC2) were identified
278	because of overall weights >1 (Table 4).
279	
280	Table 3 Accuracy of six MLs based on 39 DEGs in the training and test sets.
281	
282	Fig.4 Six ML algorithms for classification with 39 DEGs. A LASSO for eight candidate genes and the error bars
283	mean the fluctuation range of Binomial Deviance; B SVM for 13 candidate genes. C RF discriminated between
284	the control and AMI groups. And The red, black, and green lines represent the Con, out-of-bag (OOB), and AMI
285	groups respectively. D DT discriminated between the control and AMI groups. E A 6-fold GBM submodel was
286	constructed. The heat map illustrates the importance of genes in each respective submodel. The intensity of the
287	color corresponds to the significance of the gene in the particular submodel. F NN discriminated between the
288	control and AMI groups. All 39 DEGs were involved in modeling in NN, and there are ten because of space
289	limitations. If an edge is colored red, it indicates a positive correlation, meaning that the current feature positively
290	affects the classification result. Conversely, if the edge is gray, it implies a negative correlation. Furthermore, the
291	thickness of the edge signifies the weight's magnitude.
292	
293	Table 4 Overall weights of six classification models were constructed to optimize the candidate diagnostic genes.

294

295	With the basis of overall normalized weights >1, 26 candidate genes were filtered for subsequent
296	diagnosis in AMI and control groups in the training and testing sets. Among the 26 genes, 10 were
297	excluded because of no differentiation in the testing set. Sixteen genes were significant in the two
298	sets (Fig. 5).
299	
300	Fig. 5 The 16 DEGs also differed in the testing set.
301	
302	3.5 Diagnosis value of candidate genes
303	Sixteen candidate genes were included in the following ROC analysis. The AUC values of
304	SOCS3, AQP9, and ASGR2 were greater than 0.85 in both the training and testing sets. In
305	particular, 2 genes, SOCS3 and AQP9, were greater than 0.9 (Fig. 6). The AUC value of the two
306	genes indicated a potential diagnostic value in AMI.
307	
308	Fig. 6 ROC curves for AQP9, SOCS3, and ASGR2 in the training and testing sets.
309	
310	3.6 Correlation analysis
311	Immune correlation was performed with the 220 samples (Fig. 7). The infiltration landscape (Fig.
312	7A) showed 22 immune distributions in the control and AMI groups. Nine types of immune cells
313	(CD8 T cells, naive CD4 T cells, regulatory T cells (Tregs), resting NK cells, monocytes, M0
314	macrophages, M2 macrophages, eosinophils, and neutrophils) infiltrated significantly between the
315	control and AMI groups (Fig. S1). Moreover, the correlations between 22 immunized cells and

316	the two diagnostic genes, AQP9 and SOCS3, based on Spearman analysis (Fig. 7B-C) showed
317	significant correlations with 9 immune cells (monocytes, neutrophils, CD8 T cells, resting NK
318	cells, naive CD4 T cells, eosinophils, M2 macrophages, activated dendritic cells, and memory B
319	cells). More importantly, two immune cell types (monocytes and neutrophils) possessed a higher
320	correlation coefficient (Fig. 7B-C) than the other 7 immune cell types (Fig. S2-S3). In particular,
321	the correlation coefficients of monocytes (Fig. 7B-C) were highest for the two genes (0.56 for
322	SOCS3 and 0.76 for AQP9).
323	
324	Fig. 7 Immune correlation analysis of AQP9 and SOCS3 between the control and AMI groups. A The stacked
325	column graph between the control and AMI groups. B The violin plot showed 7 immune cell types infiltrated
326	differently between the control and AMI groups. C The lollipop map of the different immune cell types in AQP9
327	and SOCS3. * mean <0.05, ** mean <0.01, ***mean<0.001.
328	
329	3.7 Clinical validation

- 330 Finally, 40 individuals (20 SCAD and 20 AMI patients) were recruited. The general information of these
- 331 individuals was shown in Table 5. Among 39 clinical characteristics were summarized, and 13 had significance
- 332 between the SCAD and AMI patients, including WBC, NeP, MonP, Lym, GAT, D-dimer, CRP, SOCS3, AQP9,
- 333 LDH, cTnT, CK-MB, and Albumin.

- 334 Table 5 The general characteristics of the 40 patients.
- 335 The relative RNA levels (Fig. 8A) of AQP9 and SOCS3 were both significant. The SOCS3 content of coronary
- 336 arteries differed by the number of lesions (Fig. 8B): three lesions showed significantly higher SOCS3 than two

and one (Fig. 8B). Patients with III-IV Killip classification had higher SOCS3 compared to those with I-II (Fig.

338	8C). Although more stenotic coronary arteries were associated with higher levels of AQP9, the difference was
339	less significant than for SOCS3 (Fig. 8B). In addition, different Killip classifications associated with AQP9
340	possessed no significant differences (Fig. 8C). Furthermore, the 9 significant clinical features were analysised
341	with Pearson correlation test (Fig. S4). And SOCS3 had a positive correlation with AQP9. Both genes had a
342	negative correlation with Albumin.
343	
344	Fig. 8 Relative RNA levels of AQP9 and SOCS3 in AMI patients and SCAD controls. A The relative content of
345	SOCS3 and AQP9 in AMI patients and SCAD controls. B The comparison of AQP9 and SOCS3 in the number of
346	coronary arteries with different stenoses in AMI. C The comparison of AQP9 and SOCS3 in various Killip
346 347	coronary arteries with different stenoses in AMI. C The comparison of AQP9 and SOCS3 in various Killip classifications in AMI. * mean <0.05, ** mean <0.01, *** mean<0.001, ns mean no significance.

348

337

349 4 Discussion

350

To our knowledge, our work is the first to filter AMI diagnosis genes based on the overall normalized weights of IML. Four microarrays with 220 samples were adopted for data analysis, and further clinical studies were performed to validate the results. Two genes, AQP9 and SOCS3, showed an AUC >0.9 in both the training set and testing set (**Fig. 6**). Both genes showed a typical and highest correlation coefficient (**Fig. S2-3**) in monocytes. The clinical study verified the significance between AMI patients and healthy controls, indicating a potential diagnostic value of AQP9 and SOCS3. Compared with previous studies, we reached similar conclusions that AQP9

358	presented diagnostic value for AMI [40, 41], and we further explored the immune correlation of
359	AQP9. Additionally, Prof. Zhu [42] identified SOCS3 as an immune-related gene in AMI, and we
360	expanded it to have diagnostic value. More importantly, this study is the first to reveal the RNA
361	correlation of AQP9 and SOCS3, especially SOCS3, between the number of stenotic coronary
362	arteries and the Killip classification.
363	
364	AQP9, a cell membrane protein, transports water down the concentration gradient. ERK1/2 can
365	be reversed in AMI rats by silencing AQP9, attenuating cardiomyocytes' inflammatory response
366	and apoptosis and upregulating cardiac function [43]. The above research indicated the crucial
367	role of AQP9 in the pathogenesis of AMI. In human polymorphonuclear leukocytes, AQP9-
368	related inflammation may result from the NK-KB [44] and F-actin polymerization [45]. In our
369	work, the ROC curve of AQP9 was > 0.9 . Therefore, AQP9 might be a potential genetic marker
370	for diagnosing AMI with SCAD.
371	
372	SOCS3 is increased in AMI mice [29] and regulates the T-cell repertoire with STAT3/SOCS3
373	signalling [46]. More importantly, cardiac-specific silencing of SOCS3 triggers sustained STAT3
374	and decreases myocardial apoptosis [47]. Therefore, SOCS3 is the dominant negative modulator

[48] of Th17 via STAT3 [49]. Apoptosis regulates the pathophysiological evaluation of AMI [50].
In vitro, SOCS3 can trigger the apoptosis of mammary cells [51], and knocking out SOCS3
regulates the expression of apoptosis in 3T3-L1 preadipocytes [52]. The above research
emphasized the immune regulation of SOCS3 and the regulation of apoptosis with STAT3. In our

work, the ROC curve of SOCS3 was > 0.9. Therefore, SOCS3 might be an effective genetic
marker for diagnosing AMI.

381

382 Additionally, the CIBERSORT algorithm showed that the proportion of neutrophils and 383 monocytes in the AMI group was higher than in the control group. The progression of AMI is 384 correlated with immune disorder. For example, the white blood cell count correlates highly with 385 in-hospital mortality after AMI [53]. Neutrophils are increased in peripheral blood, and 386 researchers have emphasized that neutrophils-lymphocytes [54, 55] and monocytes/macrophages 387 [56] can be easily acquired factors for the prognosis of AMI. Macrophages were dominant in 388 infarcted myocardium, especially over the first week of AMI [57]. However, NK cells have 389 diminished cytotoxic function [58], and the targeted regulation of NK cells may indicate a 390 dominant role in the cure of AMI. At the beginning of AMI, inflammation deteriorates with 391 increased neutrophils and monocytes [59], and inflammation decreases over time with the reduced 392 function of NK cells. Innate immunity is a vital regulatory factor in the inflammatory, 393 proliferative, and maturation phases [3, 60, 61]. AMI leads to a deteriorated inflammatory process. 394 Currently, novel therapeutic interventions targeting the immune system may regulate slant 395 inflammation, which is conducive to resolving pathological conditions. In a previous clinical trial 396 of 182 NSTEMI patients (a subtype of AMI), the patient's intake of IL-1 blockers decreased acute 397 inflammation [62]. Another immune study showed that short-term blockade of S100A9 398 downregulates inflammation [63] in permanent coronary ischaemia mice. However, the above 399 immune interventions are still experimental and not in the clinic. In summary, regulating immune

400 cells along with the progression of AMI and immune intervention in AMI might be a potential401 target.

402 AQP9 expression was highest in human polymorphonuclear leukocytes [45] compared with the 403 spleen and liver, suggesting a possible correlation between AQP9 and immunity or inflammation. 404 AQP9 regulates water flow on leukocytes [64], which regulates cellular morphology and motility, 405 a change that facilitates the migration of leukocytes to inflammatory sites. Similar to our result, 406 Hawang [65] indicated the correlation between AQP9 and neutrophile granulocytes. Research [29, 407 60, 61] emphasizes the correlation between SOCS3 and neutrophils in inflammation. In our 408 research, both genes had a higher correlation with two immune cells, neutrophils and monocytes. 409 The immune cell correlation indicated that the targeted gene therapy of immune cells may benefit 410 the course of AMI-potential feasibility of using AQP9 and SOCS3 as therapeutic targets or 411 predictors of treatment response. 412 ML algorithms are widely performed for various cardiovascular diseases, such as optimizing 413 variables, classification, and congression. For variable filtration, numerous studies take only

single or double ML algorithms (e.g., weighted gene coexpression network analysis [66], LASSO, and SVM). However, only the single or double ML algorithms might unconsciously delete the potential genes. For example, AQP9 will be ignored if we only take DT because the weights of AQP9 were zero in DT (Table 4). Taking only a single ML might miss some potential genes. For example, although LASSO can detect candidate genes with big data when highly correlated features exist, the LASSO regression method tends to select one of them and ignore all the other features, leading to the instability of the results [67]. In pigmented skin lesions [68], SVM and

421	NN displayed their talent classification value. In preoperative postsurgical mortality [69], GBM is
422	optimized rather than DT, RF, and SVM. Various ML algorithms may show different weights even
423	in the same variable (Table 4). Necessarily, the overall normalized weights of IML were taken to
424	filter genes. Surprisingly, IML explores two potential, unreported diagnostic genes in AMI. In our
425	study, IML has good value in both variable screening and model prediction.

426

427 Inevitably, three limitations exist in this work, although the best efforts were taken to eliminate 428 them. Primarily, small sample size verification might possess some bias. So, multicentre 429 collaborations or leveraging larger external datasets is crutial for further verification. Although 430 testing sets and clinical validation were developed to assess the stability of the diagnostic value, 431 the bias of single-centre validation might exist. More confirmation, clinical trials and animal 432 experiments are indispensable for solid verification. Next, the ML algorithms contained 433 limitations (e.g., the black box phenomenon [70]), especially NN, which has numerous layers [71]. The set of operations an ML performs in making a prediction is unknown, even if a human knows 434 435 precisely what the model is doing at each step of the decision-making process. The operations 436 performed cannot be described in terms of human-understandable semantics. And the 437 Interpretability techniques for ML models always catch the eye of developers, which enhances the 438 transparency and reliability of the ML. Finally, limited clinical features were obtained (e.g., age 439 [72], ethnicity, and race [73]). Clinical features could potentially enhance the predictive accuracy 440 of the diagnostic model and provide a more comprehensive understanding of AMI. For example, 441 various combinations (e.g., sex, smoking or not, and laboratory indicators) of clinical variables

442 [74] are calibrated to analyze the relationship between the target variable and the outcome.

443

444 **5** Conclusion

445

446	Based on the overall normalized weights of IML, the research successfully merges four
447	microarrays and uncovers hidden diagnostic genes AQP9 and SOCS3 for leukocytes of AMI
448	patients. AQP9 and SOCS3 are closely associated with monocytes and neutrophils, which might
449	contribute to advancing AMI diagnosis and shedding light on novel genetic markers, including
450	AMI pathogenesis, targeted therapies, and potential precision medicine. Although clinical
451	validation copies the result again. Multiple clinical characteristics, multicenter, and large-sample
452	relevant trials are still needed to confirm its clinical value.

453

454 Supplementary Materials:

- 455 Table S1. The 39 DEGs in healthy controls and AMI patients.
- 456 Table S2. GSEA enrichment of 45 terms.
- 457 Table S3. GO enrichment of 160 terms.
- 458 Table S4. DO enrichment of 41 terms.
- 459 Table S5. Primary weight of DEGs in the six classification ML algorithms.
- 460 Fig. S1 Difference between the 22 immune cells.
- 461 Fig. S2. Correlation analysis of SOCS3 in 7 immune cell types.
- 462 Fig. S3. Correlation analysis of AQP9 in 7 immune cell types.

463 Fig S4. The Correlation analysis of 9 clinical variables.

464

465	Authors'	contributions:	LZ and	YL wrote	the original	draft. L	Z, KYW,	YL, JSZ,	and HLZ
-----	----------	----------------	--------	----------	--------------	----------	---------	----------	---------

- 466 performed the research. LZ, YL, XZ, and KYW analyzed the data. SQ, MH, JSZ, and HLZ
- 467 designed the experiment and revised the manuscript.

468

- 469 Founding: The research was funded by Suzhou Science & Technology Development Plan
- 470 (SYSD2019222). Zhangjiagang science and technology plan project (ZKS2135), Youth science and
- 471 technology project of Zhangjiagang Municipal Health Commission (ZJGQNKJ202211).
- 472
- 473 **Consent for publication:** This study has not been published before, and this publication has been
- 474 approved by all authors.

475

- 476 Ethics approval and consent to participate
- 477 The clinical trial part was approved by the Ethics Review Committee of Jinghai District Hospital.
- 478

479 Availability of data and material

- 480 The datasets presented in this study can be found online. The names of the repositories and GEO
- 481 numbers can be found below: <u>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59867;</u>
- 482 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60993;https://www.ncbi.nlm.nih.gov/g
- 483 <u>eo/query/acc.cgi?acc=GSE62646;https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4806</u>

484	0.

485

486 Competing of intere	sts:
--------------------------------	------

487 The authors declare that they have no conflicts of interest.

488

489 Abbreviation:

- 490 AUC: Area under the Curve; AMI: Acute Myocardial Infarction; IML: Integration Machine
- 491 Learning; DEGs: Differently Expressed Genes; KEGG-GSEA: Kyoto Encyclopedia of Genes and
- 492 Genomes-Gene Set Enrichment Analysis; GO: Gene Ontology; DO: Disease Ontology; MF:
- 493 Molecular Function; BP: Biological Process; CC: Cellular Components; SVM: Support Vector
- 494 Machine; ML: Machine Learning; LASSO: Least Absolute Shrinkage and Selection Operator; RF:
- 495 Random Forest; GBM: Gradient Boosting Machine; DT: Decision Trees; NN: Neural Network.

496

497 Acknowledgments

498 We thank Suzhou Science & Technology Development Plan.

499

500 References

- 5011.Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases502and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-5032017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018,504392:1859-1922.
- Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, Abera SF,
 Aboyans V, Abraham JP, Abubakar I, Abu-Raddad LJ, et al: Global, regional, and national
 disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life
 expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological
 transition. Lancet 2015, 386:2145-2191.

510 3. Reed GW, Rossi JE, Cannon CP: Acute myocardial infarction. Lancet 2017, 389:197-210.

- 4. Anderson JL, Morrow DA: Acute Myocardial Infarction. N Engl J Med 2017, 376:20532064.
- 513 5. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA,
- 514 Mack MJ, Mauri L, et al: 2016 ACC/AHA Guideline Focused Update on Duration of Dual
- 515 Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the
- 516American College of Cardiology/American Heart Association Task Force on Clinical517Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for518Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery519Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the520Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013
- 521ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014522AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute523Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular524Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation5252016, 134:e123-155.
- 526 6. Huang CC, Liao PC: Heart Attack Causes Head-Ache Cardiac Cephalalgia. Acta 527 Cardiol Sin 2016. **32:**239-242.
- Di Stefano R, Di Bello V, Barsotti MC, Grigoratos C, Armani C, Dell'Omodarme M, Carpi A,
 Balbarini A: Inflammatory markers and cardiac function in acute coronary syndrome:
 difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI
 models. *Biomed Pharmacother* 2009, 63:773-780.
- 532 8. Wei EY, Hira RS, Huang HD, Wilson JM, Elayda MA, Sherron SR, Birnbaum Y: Pitfalls in
 533 diagnosing ST elevation among patients with acute myocardial infarction. J
 534 Electrocardiol 2013, 46:653-659.
- Moy E, Barrett M, Coffey R, Hines AL, Newman-Toker DE: Missed diagnoses of acute
 myocardial infarction in the emergency department: variation by patient and facility
 characteristics. *Diagnosis (Berl)* 2015, 2:29-40.
- 538 10. Peet C, Ivetic A, Bromage DI, Shah AM: Cardiac monocytes and macrophages after
 539 myocardial infarction. *Cardiovasc Res* 2020, 116:1101-1112.
- Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P,
 van der Laan AM, et al: Differential contribution of monocytes to heart macrophages in
 steady-state and after myocardial infarction. *Circ Res* 2014, 115:284-295.
- Jiang K, Tu Z, Chen K, Xu Y, Chen F, Xu S, Shi T, Qian J, Shen L, Hwa J, et al: Gasdermin
 D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial
 infarction. J Clin Invest 2022, 132.
- Liang Y, Chen H, Wang P: Correlation of Leukocyte and Coronary Lesion Severity of
 Acute Myocardial Infarction. *Angiology* 2018, 69:591-599.
- Kazimierczyk E, Eljaszewicz A, Zembko P, Tarasiuk E, Rusak M, Kulczynska-Przybik A,
 Lukaszewicz-Zajac M, Kaminski K, Mroczko B, Szmitkowski M, et al: The relationships
 among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute
 myocardial infarction. *Pharmacol Rep* 2019, **71**:73-81.
- 552 15. Sreejit G, Abdel-Latif A, Athmanathan B, Annabathula R, Dhyani A, Noothi SK, Quaife-Ryan

553		GA, Al-Sharea A, Pernes G, Dragoljevic D, et al: Neutrophil-Derived S100A8/A9 Amplify
554		Granulopoiesis After Myocardial Infarction. Circulation 2020, 141:1080-1094.
555	16.	Long R, Gao L, Li Y, Li G, Qin P, Wei Z, Li D, Qian C, Li J, Yang G: M2 macrophage-
556		derived exosomes carry miR-1271-5p to alleviate cardiac injury in acute myocardial
557		infarction through down-regulating SOX6. Mol Immunol 2021, 136:26-35.
558	17.	Li R, Jin J, Liu E, Zhang J: A novel circulating biomarker Inc-MALAT1 for acute
559		myocardial infarction: Its relationship with disease risk, features, cytokines, and major
560		adverse cardiovascular events. J Clin Lab Anal 2022, 36:e24771.
561	18.	Global, regional, and national incidence, prevalence, and years lived with disability for
562		354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic
563		analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392:1789-1858.
564	19.	Lu Y, Wu Q, Liao J, Zhang S, Lu K, Yang S, Wu Y, Dong Q, Yuan J, Zhao N, Du Y:
565		Identification of the distinctive role of DPT in dilated cardiomyopathy: a study based on
566		bulk and single-cell transcriptomic analysis. Ann Transl Med 2021, 9:1401.
567	20.	Di Z, Di M, Fu W, Tang Q, Liu Y, Lei P, Gu X, Liu T, Sun M: Integrated Analysis Identifies
568		a Nine-microRNA Signature Biomarker for Diagnosis and Prognosis in Colorectal
569		Cancer. Front Genet 2020, 11:192.
570	21.	Wang K, Zhang L, Li L, Wang Y, Zhong X, Hou C, Zhang Y, Sun C, Zhou Q, Wang X:
571		Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays
572		Based on Machine Learning and Bioinformatics Analysis. Int J Mol Sci 2022, 23.
573	22.	Zhang L, Lin Y, Wang K, Han L, Zhang X, Gao X, Li Z, Zhang H, Zhou J, Yu H, Fu X:
574		Multiple-model machine learning identifies potential functional genes in dilated
575		cardiomyopathy. Front Cardiovasc Med 2022, 9:1044443.
576	23.	Zhang L, Mao R, Lau CT, Chung WC, Chan JCP, Liang F, Zhao C, Zhang X, Bian Z:
577		Identification of useful genes from multiple microarrays for ulcerative colitis diagnosis
578		based on machine learning methods. Sci Rep 2022, 12:9962.
579	24.	DeLong JH, Ohashi SN, O'Connor KC, Sansing LH: Inflammatory Responses After
580		Ischemic Stroke. Semin Immunopathol 2022, 44:625-648.
581	25.	Denorme F, Portier I, Rustad JL, Cody MJ, de Araujo CV, Hoki C, Alexander MD, Grandhi R,
582		Dyer MR, Neal MD, et al: Neutrophil extracellular traps regulate ischemic stroke brain
583		injury. J Clin Invest 2022, 132.
584	26.	Swirski FK, Nahrendorf M: Leukocyte behavior in atherosclerosis, myocardial infarction,
585		and heart failure. Science 2013, 339:161-166.
586	27.	Hiremath A, Shiradkar R, Fu P, Mahran A, Rastinehad AR, Tewari A, Tirumani SH, Purysko
587		A, Ponsky L, Madabhushi A: An integrated nomogram combining deep learning, Prostate
588		Imaging-Reporting and Data System (PI-RADS) scoring, and clinical variables for
589		identification of clinically significant prostate cancer on biparametric MRI: a
590		retrospective multicentre study. Lancet Digit Health 2021, 3:e445-e454.
591	28.	Wang Y, Guan Q, Lao I, Wang L, Wu Y, Li D, Ji Q, Wang Y, Zhu Y, Lu H, Xiang J: Using
592		deep convolutional neural networks for multi-classification of thyroid tumor by
593		histopathology: a large-scale pilot study. Ann Transl Med 2019, 7:468.
594	29.	Zhu X, Yin T, Zhang T, Zhu Q, Lu X, Wang L, Liao S, Yao W, Zhou Y, Zhang H, Li X:
595		Identification of Immune-Related Genes in Patients with Acute Myocardial Infarction

596		Using Machine Learning Methods. J Inflamm Res 2022, 15:3305-3321.
597	30.	Ein-Dor L, Kela I, Getz G, Givol D, Domany E: Outcome signature genes in breast cancer:
598		is there a unique set? Bioinformatics 2005, 21:171-178.
599	31.	Tang G, Qi L, Sun Z, Liu J, Lv Z, Chen L, Huang B, Zhu S, Liu Y, Li Y: Evaluation and
600		analysis of incidence and risk factors of lower extremity venous thrombosis after
601		urologic surgeries: A prospective two-center cohort study using LASSO-logistic
602		regression. Int J Surg 2021, 89:105948.
603	32.	Zhou S: Sparse SVM for Sufficient Data Reduction. IEEE Trans Pattern Anal Mach Intell
604		2022, 44: 5560-5571.
605	33.	Rosenblatt WH, Yanez ND: A Decision Tree Approach to Airway Management Pathways
606		in the 2022 Difficult Airway Algorithm of the American Society of Anesthesiologists.
607		Anesth Analg 2022, 134:910-915.
608	34.	Utkin LV, Konstantinov AV: Attention-based random forest and contamination model.
609		Neural Netw 2022, 154: 346-359.
610	35.	Kriegeskorte N, Golan T: Neural network models and deep learning. Curr Biol 2019,
611		29: R231-r236.
612	36.	Dash TK, Chakraborty C, Mahapatra S, Panda G: Gradient Boosting Machine and Efficient
613		Combination of Features for Speech-Based Detection of COVID-19. IEEE J Biomed
614		Health Inform 2022, 26:5364-5371.
615	37.	Jaatinen T, Laine J: Isolation of mononuclear cells from human cord blood by Ficoll-
616		Paque density gradient. Curr Protoc Stem Cell Biol 2007, Chapter 2: Unit 2A.1.
617	38.	Tan YS, Lei YL: Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density
618		Gradient Centrifugation. Methods Mol Biol 2019, 1960:93-99.
619	39.	Sugiyama Y, Yamazaki K, Kusaka-Kikushima A, Nakahigashi K, Hagiwara H, Miyachi Y:
620		Analysis of aquaporin 9 expression in human epidermis and cultured keratinocytes.
621		FEBS Open Bio 2014, 4: 611-616.
622	40.	Chen J, Yu L, Zhang S, Chen X: Network Analysis-Based Approach for Exploring the
623		Potential Diagnostic Biomarkers of Acute Myocardial Infarction. Front Physiol 2016,
624		7:615.
625	41.	Shao G: Integrated RNA gene expression analysis identified potential immune-related
626		biomarkers and RNA regulatory pathways of acute myocardial infarction. PLoS One
627		2022, 17: e0264362.
628	42.	Yang Y, Liu P, Teng R, Liu F, Zhang C, Lu X, Ding Y: Integrative bioinformatics analysis
629		of potential therapeutic targets and immune infiltration characteristics in dilated
630		cardiomyopathy. Ann Transl Med 2022, 10:348.
631	43.	Huang X, Yu X, Li H, Han L, Yang X: Regulation mechanism of aquaporin 9 gene on
632		inflammatory response and cardiac function in rats with myocardial infarction through
633		extracellular signal-regulated kinase1/2 pathway. Heart Vessels 2019, 34:2041-2051.
634	44.	Takeuchi K, Hayashi S, Matumoto T, Hashimoto S, Takayama K, Chinzei N, Kihara S,
635		Haneda M, Kirizuki S, Kuroda Y, et al: Downregulation of aquaporin 9 decreases catabolic
636		factor expression through nuclear factor $\Box \kappa B$ signaling in chondrocytes. Int J Mol Med
637		2018, 42: 1548-1558.
638	45.	Matsushima A, Ogura H, Koh T, Shimazu T, Sugimoto H: Enhanced expression of

639		aquaporin 9 in activated polymorphonuclear leukocytes in patients with systemic
640		inflammatory response syndrome. Shock 2014, 42:322-326.
641	46.	Baker BJ, Akhtar LN, Benveniste EN: SOCS1 and SOCS3 in the control of CNS immunity.
642		Trends Immunol 2009, 30:392-400.
643	47.	Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M,
644		Oshima Y, Nakaoka Y, et al: Activation of signal transducer and activator of transcription
645		3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through
646		the upregulation of manganese superoxide dismutase. Circulation 2001, 104:979-981.
647	48.	Yoshimura A, Naka T, Kubo M: SOCS proteins, cytokine signalling and immune
648		regulation. Nat Rev Immunol 2007, 7:454-465.
649	49.	Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A,
650		Hennighausen L, O'Shea JJ: Selective regulatory function of Socs3 in the formation of IL-
651		17-secreting T cells. Proc Natl Acad Sci U S A 2006, 103:8137-8142.
652	50.	Scarabelli TM, Stephanou A, Pasini E, Comini L, Raddino R, Knight RA, Latchman DS:
653		Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes
654		during ischemia/reperfusion injury. Circ Res 2002, 90:745-748.
655	51.	Le Provost F, Miyoshi K, Vilotte JL, Bierie B, Robinson GW, Hennighausen L: SOCS3
656		promotes apoptosis of mammary differentiated cells. Biochem Biophys Res Commun 2005,
657		338: 1696-1701.
658	52.	Chhabra JK, Chattopadhyay B, Paul BN: SOCS3 dictates the transition of divergent time-
659		phased events in granulocyte TNF-α signaling. Cell Mol Immunol 2014, 11:105-106.
660	53.	Dutta P, Nahrendorf M: Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol
661		2015, 35: 1066-1070.
662	54.	Lin G, Dai C, Xu K, Wu M: Predictive value of neutrophil to lymphocyte ratio and red
663		cell distribution width on death for ST segment elevation myocardial infarction. Sci Rep
664		2021, 11: 11506.
665	55.	Sasmita BR, Zhu Y, Gan H, Hu X, Xue Y, Xiang Z, Huang B, Luo S: Prognostic value of
666		neutrophil-lymphocyte ratio in cardiogenic shock complicating acute myocardial
667		infarction: A cohort study. Int J Clin Pract 2021, 75:e14655.
668	56.	Kervinen H, Mänttäri M, Kaartinen M, Mäkynen H, Palosuo T, Pulkki K, Kovanen PT:
669		Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation
670		markers in patients with acute coronary syndromes. Am J Cardiol 2004, 94:993-996.
671	57.	Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A,
672		Shinmura K, Shen W, et al: Temporal dynamics of cardiac immune cell accumulation
673		following acute myocardial infarction. J Mol Cell Cardiol 2013, 62:24-35.
674	58.	Ortega-Rodríguez AC, Marín-Jáuregui LS, Martínez-Shio E, Hernández Castro B, González-
675		Amaro R, Escobedo-Uribe CD, Monsiváis-Urenda AE: Altered NK cell receptor repertoire
676		and function of natural killer cells in patients with acute myocardial infarction: A three-
677		month follow-up study. Immunobiology 2020, 225:151909.
678	59.	Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins
679		C, Iwamoto Y, et al: Rapid monocyte kinetics in acute myocardial infarction are
680		sustained by extramedullary monocytopoiesis. J Exp Med 2012, 209:123-137.
681	60.	Nahrendorf M: Myeloid cell contributions to cardiovascular health and disease. Nat Med

682		2018, 24: 711-720.
683	61.	Swirski FK, Nahrendorf M: Cardioimmunology: the immune system in cardiac
684		homeostasis and disease. Nat Rev Immunol 2018, 18:733-744.
685	62.	Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-
686		1135.
687	63.	Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F,
688		Nicolau J, Koenig W, Anker SD, et al: Antiinflammatory Therapy with Canakinumab for
689		Atherosclerotic Disease. N Engl J Med 2017, 377:1119-1131.
690	64.	Moniaga CS, Watanabe S, Honda T, Nielsen S, Hara-Chikuma M: Aquaporin-9-expressing
691		neutrophils are required for the establishment of contact hypersensitivity. Sci Rep 2015,
692		5: 15319.
693	65.	Wang H, Dou S, Wang C, Gao W, Cheng B, Yan F: Identification and Experimental
694		Validation of Parkinson's Disease with Major Depressive Disorder Common Genes. Mol
695		Neurobiol 2023, 60: 6092-6108.
696	66.	Radulescu E, Jaffe AE, Straub RE, Chen Q, Shin JH, Hyde TM, Kleinman JE, Weinberger
697		DR: Identification and prioritization of gene sets associated with schizophrenia risk by
698		co-expression network analysis in human brain. Mol Psychiatry 2020, 25:791-804.
699	67.	Choi BY, Bair E, Lee JW: Nearest shrunken centroids via alternative genewise shrinkages.
700		PLoS One 2017, 12: e0171068.
701	68.	Dreiseitl S, Ohno-Machado L, Kittler H, Vinterbo S, Billhardt H, Binder M: A comparison of
702		machine learning methods for the diagnosis of pigmented skin lesions. J Biomed Inform
703		2001, 34: 28-36.
704	69.	Chiew CJ, Liu N, Wong TH, Sim YE, Abdullah HR: Utilizing Machine Learning Methods
705		for Preoperative Prediction of Postsurgical Mortality and Intensive Care Unit
706		Admission. Ann Surg 2020, 272:1133-1139.
707	70.	Regazzoni F, Chapelle D, Moireau P: Combining data assimilation and machine learning
708		to build data-driven models for unknown long time dynamics-Applications in
709		cardiovascular modeling. Int J Numer Method Biomed Eng 2021, 37:e3471.
710	71.	Peng JC, Ran ZH, Shen J: Seasonal variation in onset and relapse of IBD and a model to
711		predict the frequency of onset, relapse, and severity of IBD based on artificial neural
712		network. Int J Colorectal Dis 2015, 30:1267-1273.
713	72.	Kalkan IH, Dağli U, Oztaş E, Tunç B, Ulker A: Comparison of demographic and clinical
714		characteristics of patients with early vs. adult vs. late onset ulcerative colitis. Eur J Intern
715		Med 2013, 24: 273-277.
716	73.	Jiang L, Xia B, Li J, Ye M, Deng C, Ding Y, Luo H, Ren H, Hou X, Liu H, et al: Risk factors
717		for ulcerative colitis in a Chinese population: an age-matched and sex-matched case-
718		control study. J Clin Gastroenterol 2007, 41:280-284.
719	74.	Adler ED, Voors AA, Klein L, Macheret F, Braun OO, Urey MA, Zhu W, Sama I, Tadel M,
720		Campagnari C, et al: Improving risk prediction in heart failure using machine learning.
721		Eur J Heart Fail 2020, 22: 139-147.

722

724

Table 1 List of primers for real-time PCR analysis in GAPDH, AQP9, and SOCS3.

Gene		Primer sequences							
GAPDH	F:	TGTGGGCATCAATGGATTTGG	R:	ACACCATGTATTCCGGGTCAAT					
AQP9	F:	GCCATCGGCCTCCTGATTAT	R:	GCCCACTACAGGAATCCACC					
SOCS3	F:	TCCAAACAGGGGACACTTCG	R:	GGGGGTGTGACCATTTCCTT					

725

Table 2 Fundamental information in the 4 datasets.

ID	Public time	Institution	Plat form	Count ry	C o n	A M I	Microarray/RNA-seq method
GSE5 9867	21- May- 15	Institute of Biochemistry and Biophysics	GPL 6244	Poland	46	11 1	Affymetrix GCS 3000 GeneArray Scanner
GSE6 0993	23- May- 15	Ajou University of Korea	GPL 6884	South Korea	7	7	HumanHT-12 v3 Expression BeadChip
GSE6 2646	23- Oct-14	Institute of Biochemistry and Biophysics	GPL 6244	Poland	0	28	Affymetrix GCS 3000 GeneArray Scanner
GSE4 8060	28- Feb- 14	Mayo Clinic	GPL 570	USA	21	0	GeneChip Scanner 3000 7G

726

727

Table 3 Accuracy of six MLs based on 39 DEGs in the training and test sets.

MLs	Training sets (%)	Testing sets (%)
LASSO	70.7	70.7
SVM	88.46	91.84
RF	98.09	100
DT	94.27	75.52
GBM	93.3	85.71
NN	83.74	71.43

728 Table 4 Overall weights of six classification models were constructed to optimize the candidate diagnostic genes.

ID	SVM	RF	NN	GBM	DT	LASSO	Overall weights
ASGR2	1	1	0.97	0.21	1	0.61	4.79
SOCS3	0.98	0.34	0.52	0.24	0.59	0.61	3.28
AQP9	0.61	0.1	0.68	1	0	0.52	2.91
PPARG	0.76	0.15	1	0.25	0	0.5	2.66
RNASE1	0.74	0.22	0.24	0.1	0.41	0.74	2.45
DYSF	0.2	0.68	0.01	0.57	0	0.72	2.18
S100A9	0.53	0.09	0.01	0.74	0	0.63	2
FCGR1A	0.17	0.51	0	0.57	0	0.68	1.93
VSIG4	0.44	0.3	0.1	0.19	0.01	0.86	1.9
STAB1	0.47	0.58	0.05	0.14	0	0.61	1.85
MYBL1	0.68	0.15	0.2	0	0.26	0.52	1.81
KLRD1	0.26	0.65	0.01	0.05	0	0.73	1.7
ECRP	0.44	0.24	0.11	0	0.34	0.54	1.67
TCN2	0.46	0.27	0.07	0	0	0.78	1.58
FAM20A	0.31	0.08	0.15	0	0	1	1.54
MERTK	0.19	0.21	0.01	0.1	0.14	0.71	1.36
HP	0.09	0.78	0	0	0	0.45	1.32
RNASE2	0.16	0.42	0.01	0	0	0.7	1.29
DTHD1	0.13	0.45	0.05	0	0	0.66	1.29
CLC	0.11	0.72	0.02	0	0	0.36	1.21
SNORD20	0.14	0.24	0.01	0.13	0.1	0.5	1.12
CD163	0.15	0.29	0	0.11	0	0.57	1.12
NRG1	0.2	0.25	0.02	0	0	0.63	1.1
SNORD45B	0.12	0.64	0.01	0	0	0.33	1.1
CYP1B1	0.14	0.25	0	0	0	0.66	1.05
KLRC2	0.07	0.51	0	0	0	0.46	1.04

TMEM176A	0.08	0.67	0	0	0	0.24	0.99	
SLED1	0.09	0.24	0.02	0.05	0	0.49	0.89	
FCGR1A.2	0.23	0	0	0.62	0	0	0.85	
SERPINB2	0.08	0.21	0	0	0	0.54	0.83	
FCGR1A.1	0.18	0	0	0.62	0	0	0.8	
KLRC4	0.13	0.21	0	0	0	0.43	0.77	
KLRA1P	0.1	0.07	0	0.08	0	0.51	0.76	
MIR21	0.08	0.09	0.01	0	0	0.5	0.68	
CES1	0.12	0.05	0.03	0	0	0.47	0.67	
KLRC4-KLRK1	0.07	0	0	0.08	0	0.43	0.58	
KLRC3	0.07	0.1	0	0	0	0.39	0.56	
NRG1.1	0.13	0	0	0	0	0	0.13	
FMN1.1	0.07	0	0.01	0	0	0	0.08	

736			
735			
734			
733			
732			
731			
730			
729			

Diabetes mellitus, %	6.00(30)	7.00(35)	>0.05
Stroke, %	4.00(20)	4.00(20)	>0.05
Hyperlipemia, %	4.00(20)	6.00(30)	>0.05
Age, year	66 (63, 72)	70 (58, 77)	>0.05
Sex (Male), %	10.00(50.00)	12.00(60.00)	>0.05
RBC, million cells/µL	4.37 (3.80, 4.49)	4.03 (3.55, 4.35)	>0.05
WBC, 1000 cells/µL	6.02 (4.85, 6.84)	8.33 (6.84, 11.24)	< 0.001
NeP, %	69 (58, 74)	80 (75, 86)	< 0.001
MonP, %	8.00 (6.15, 9.23)	5.55 (3.98, 7.68)	< 0.05
Mon, 1000 cells/µL	0.44 (0.35, 0.48)	0.42 (0.19, 0.73)	>0.05
Lym, 1000 cells/µL	1.37 (1.06, 1.77)	0.96 (0.62, 1.42)	$<\!\!0.05$
RDW, %	13.00 (12.55, 13.30)	13.55 (12.88, 14.98)	>0.05
PDW, %	11.85 (10.48, 13.90)	13.25 (11.68, 16.15)	>0.05
Pla, 1000 cells/µL	214 (163, 245)	219 (173, 244)	>0.05
MCHC, g/L	334 (329, 342)	329 (319, 338)	>0.05
Hg, g/L	131 (113, 140)	119 (109, 134)	>0.05
GAT, U/L	16 (14, 21)	28 (17, 51)	< 0.05
D-dimer, mg/L	0.46 (0.27, 0.69)	1.01 (0.62, 2.70)	< 0.01
CRP, mg/L	1 (1, 2)	12 (7, 26)	< 0.001
SOCS3	1.57 (1.22, 1.76)	1.97 (1.86, 2.20)	< 0.001
AQP9	0.90 (0.85, 1.03)	1.44 (1.16, 1.66)	< 0.001
LDH, U/L	152 (141, 194)	260 (228, 303)	< 0.001
cTnT, µg/mL	12 (9, 18)	140 (92, 264)	< 0.001
CK-MB, U/L	2 (1, 4)	19 (9, 33)	< 0.001
LDL, mmol/L	1.83 (1.57, 2.68)	2.38 (1.74, 3.62)	>0.05
HDL, mmol/L	1.04 (0.96, 1.16)	1.11 (0.96, 1.34)	>0.05
TC, mmol/L	3.59 (2.87, 4.52)	4.15 (3.27, 5.80)	>0.05
TG, mmol/L	1.13 (0.71, 1.58)	0.98 (0.89, 1.22)	>0.05
Glucose, mg/L	5.36 (4.73, 5.81)	6.05 (5.12, 9.15)	>0.05
Cys,µmol/L	11.7 (10.1, 16.4)	14.2 (8.7, 22.1)	>0.05
Albumin, g/L	41.8 (38.9, 43.3)	38.6 (34.9, 40.3)	< 0.01
Total protein, g/L	65 (63, 67)	65 (60, 67)	>0.05
GGT, U/L	13 (11, 22)	17 (12, 33)	>0.05
IBIL, μmol/L	3.65 (2.50, 6.03)	4.95 (3.50, 7.30)	>0.05
DBIL,µmol/L	4.00 (2.58, 4.78)	4.30 (2.85, 7.75)	>0.05
IBIL,µmol/L	7.8 (5.2, 10.7)	10.0 (6.3, 17.4)	>0.05
Globulin, g/L	24.7 (21.2, 25.8)	25.6 (23.5, 26.9)	>0.05
ALP, U/L	72 (61, 87)	87 (72, 108)	>0.05

RBC; red blood cell count, WBC; white blood cell count, NeP; neutrophils percentage, MonP; monocyte percentage, Mon; monocyte count, Lym; lymphocyte count, RDW; red blood cell distribution width, PDW; platelet distribution width, Pla; platelet count, MCHC; mean corpuscular haemoglobin concentration, Hg; haemoglobin, GAT; glutamic transaminase, CRP; c-reactive protein, LDH; lactate dehydrogenase, cTnT; cardiac troponin t, CK-MB; creatine kinase isoenzymes, LDL; low-density lipoprotein, HDL; high-density lipoprotein, TC; total cholesterol, TG; total triglycerides, Cys; homocysteine, GGT; gammaglutaminase, IBIL; indirect bilirubin, DBIL; direct bilirubin, IBIL; total bile acid, ALP; alkaline phosphatase.

739



Α



B

Down

Not

Up













-0.4 -0.2 0.0 0.2 Correlation Coefficient

NK cells resting

С

-0.6

AQP9

<0.001

abs(cor)

• 0.1

• 0.2

0.3
0.4
0.5

pvalue

0

0.2

04

0.6

0.8

1

0.6

0.4









